Sign up to save your podcasts
Or
Share Avalo Therapeutics is developing a high affinity IL-1β for hidradenitis suppurativa - key phase 2 data will come next year
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Avalo Therapeutics is developing a high affinity IL-1β for hidradenitis suppurativa - key phase 2 data will come next year
CEO Garry Neil describes the target and how he believes Avalo's therapy has especially high affinity. Approximately 1% of the population is believe to have HS.
View all episodes
By BiotechTV
4.3
77 ratings
CEO Garry Neil describes the target and how he believes Avalo's therapy has especially high affinity. Approximately 1% of the population is believe to have HS.
More shows like BiotechTV - News
View all
WSJ What’s News
4,420 Listeners
The a16z Show
1,105 Listeners
The Meb Faber Show - Better Investing
943 Listeners
The Daily
113,121 Listeners
The Readout Loud
337 Listeners
The Intelligence from The Economist
2,592 Listeners
The Prof G Pod with Scott Galloway
5,610 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
10,254 Listeners
Business Of Biotech
85 Listeners
BioCentury This Week
34 Listeners
Biotech Hangout
21 Listeners
BG2Pod with Brad Gerstner and Bill Gurley
475 Listeners
Prof G Markets
1,480 Listeners
The BioCentury Show
11 Listeners
The Studio at Kendall Square
0 Listeners
Off-Target Effects with Matt Gline
4 Listeners
Biotech CEO Sisterhood
3 Listeners
BioVenture VoiCes with Chris Garabedian
7 Listeners